Episode 22: Accelerating Innovation — The New Era of AI-Driven Drug Discovery

Early detection of cancer and other diseases can significantly improve patient prognosis. Join us for a practical discussion about the challenges of developing noninvasive early screening tools, from biomarker identification to clinical performance.

The relatively high failure rate of new candidate drugs is a key issue in pharma and biopharma R&D. Listen in as we discuss how artificial intelligence, machine learning, and the ever-increasing availability of biological datasets can improve prospects.

Precision medicine is a multifaceted approach to designing and delivering individualized patient treatments. Using multi-omic, environmental, lifestyle, and other data, researchers aim to more accurately develop treatment and prevention strategies tailored to each unique patient. The promise of pre…

Digital therapeutics are software-driven, evidence-based products used to prevent, manage, or treat a medical disease or disorder. Digital therapeutics enable patients to be more aware of and play a more active role in managing their health and can improve access for patients for whom visiting a cl…